SCHEMBL3709012

SCHEMBL3709012

O=S(=O)(Nc1cc[c]cc1)c1c(Cl)cccc1Cl

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.58
GAA P10253 1/20 0.55
ALDH1A1 P00352 3/20 0.47
LMNA P02545 1/20 0.47
MCL1 Q07820 1/20 0.44
SLC40A1 Q9NP59 1/20 0.44
PGR P06401 3/20 0.43
MEN1 O00255 1/20 0.42
MAPT P10636 1/20 0.42
PKM P14618 1/20 0.42
KMT2A Q03164 1/20 0.42
SLC22A12 Q96S37 2/20 0.40
CES1 P23141 1/20 0.39
CCR4 P51679 1/20 0.39
SLC1A3 P43003 1/20 0.39
SLC1A2 P43004 1/20 0.39
CYP19A1 P11511 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL132296 0.79 ATM (0.62) ATMGAAALDH1A1LMNAMCL1
SCHEMBL29053323 0.79 ATM (0.67) ATMGAAALDH1A1LMNAMCL1
SCHEMBL5046668 0.75 PGR (0.73) ALDH1A1LMNAPGRMAPTPKM
SCHEMBL4142277 0.73 CES1 (0.75) ALDH1A1PGRMAPTCES1CYP19A1
SCHEMBL5046807 0.72 MAPT (0.58) ALDH1A1LMNAPGRMEN1MAPT
SCHEMBL31575982 0.72 GAA (0.52) ATMGAAALDH1A1PGRMEN1
SCHEMBL31576015 0.72 ATM (0.55) ATMGAAALDH1A1LMNASLC40A1
SCHEMBL28530757 0.72 HTR6 (0.61) ATMGAAALDH1A1LMNAMCL1
SCHEMBL3709011 0.72 ATM (0.44) ATMGAAALDH1A1LMNAMCL1
SCHEMBL3268657 0.72 MAPT (0.61) ALDH1A1LMNAMCL1SLC40A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120165334-A1 Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors AMGEN INC. (US) 2012-06-28 US claimed
EP-2398791-A1 INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS Amgen, Inc (US) 2011-12-28 EP claimed
WO-2010096314-A1 INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS AMGEN INC. (US) 2010-08-26 WO claimed
US-20120165334-A1 Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors AMGEN INC. (US) 2012-06-28 US disclosed
EP-2398791-A1 INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS Amgen, Inc (US) 2011-12-28 EP disclosed
WO-2010096314-A1 INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS AMGEN INC. (US) 2010-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165334-A1 Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors MTOR, PIKFYVE, RICTOR ATM 244/4885GAA 1461/4885ALDH1A1 4371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.